Drug Trial Radar · NCT06314698
Narlumosbart Compared With Denosumab in Patients With Multiple Myeloma Bone Disease
Last checked: Nov 19, 2026Latest source record: Mar 18, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
478
Planned (sponsor's estimate)
Start
Apr 1, 2024
Primary completion
Dec 31, 2024
Study completion Apr 30, 2027
Sponsor
- Lead sponsor
- RenJi HospitalAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Shanghai JMT-Bio Inc.
- First posted
- Mar 18, 2024
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Supportive care
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to determine if narlumosbart is non-inferior to denosumab in the treatment of bone diseases from multiple myeloma (MM).
Conditions
- Multiple Myeloma
- Bone Diseases
Interventions
NarlumosbartDrug
Administered by subcutaneous injection once every 4 weeks.
DenosumabDrug
Administered by subcutaneous injection once every 4 weeks.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percent change from baseline in urinary N-terminal telopeptide of type 1 collagen corrected for urinary creatinine (uNTx/uCr) at week 13Time frame: From baseline to week 13
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.